Health reporter Philippa Roxby shared that a new drug is now available on the NHS in England for one of the most common types of advanced breast cancer. Capivasertib has shown promising results in slowing down the progression of the disease and shrinking tumors in 25% of patients, with approximately 3,000 women benefiting from it annually. Following a successful clinical trial, England’s drug assessment body approved funding for the drug, providing another treatment option for individuals with incurable cancer that has spread.
Breast cancer is a prevalent form of cancer in the UK, affecting one in seven women during their lifetimes. Despite its prevalence, advancements in treatments such as chemotherapy, radiotherapy, and targeted therapies have significantly improved outcomes for those with the disease. Capivasertib, a targeted therapy, obstructs the activity of a protein molecule called AKT that promotes cancer growth. Researchers have been developing the drug for over two decades and consider it one of the most effective options for advanced cancer, with the potential to provide long-lasting benefits lasting months to possibly even years.
Linda Kelly, a 67-year-old woman with breast cancer that has spread to her bones and chest wall, shared her positive experience with capivasertib. The drug has provided Linda with nearly four additional years of life, allowing her to maintain a sense of normalcy and pursue activities she enjoys, like cycling and pilates. While capivasertib is suitable for individuals with specific gene mutations affecting half of those with hormone receptor positive secondary breast cancer, it may not be suitable for everyone. NHS England’s Clinical Director for Cancer, Professor Peter Johnson, emphasized that capivasertib offers an additional treatment option for those whose cancer has progressed despite previous therapies.
Despite initial challenges in accessing capivasertib due to delays in approval, charity Breast Cancer Now’s Chief Executive Claire Rowney expressed delight in the drug providing hope to individuals seeking more time to engage in meaningful activities. Rowney urged prompt genetic testing implementation by NHS England to ensure eligible patients promptly receive capivasertib without further delays. Additionally, she called for Scotland to expedite funding approval to ensure patients across the UK have equitable access to the treatment
Read the full article from The BBC here: Read More
